Cencora, Inc.
Cencora, Inc., headquartered in the United States, is a prominent player in the global pharmaceutical and life sciences industry. Founded in 2022, the company has quickly established itself as a leader in providing comprehensive supply chain solutions, clinical trial services, and logistics for biopharmaceutical products. With a strong operational presence across North America, Europe, and Asia, Cencora is dedicated to enhancing patient access to innovative therapies. Cencora's unique offerings include temperature-controlled logistics and tailored distribution services, ensuring the integrity of sensitive products throughout the supply chain. The company’s commitment to quality and efficiency has earned it a notable position in the market, recognised for its ability to streamline processes and reduce time-to-market for critical medications. As Cencora continues to grow, it remains focused on delivering exceptional value to its partners and clients in the ever-evolving healthcare landscape.
DitchCarbon Score
How does Cencora, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cencora, Inc.'s score of 42 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cencora, Inc.'s reported carbon emissions
In 2024, Cencora, Inc. reported total carbon emissions of approximately 135,087,000 kg CO2e for Scope 1, 88,699,000 kg CO2e for Scope 2 (market-based), and a significant 40,504,539,000 kg CO2e for Scope 3 emissions. This reflects a comprehensive approach to emissions reporting, covering all three scopes of greenhouse gas emissions. Cencora has set ambitious climate commitments, aiming for a 54.6% reduction in absolute Scope 1 and 2 greenhouse gas emissions by FY2032, using FY2019 as the baseline. Additionally, the company has pledged that 82% of its suppliers by spend will have science-based targets by FY2027. These targets align with the Science Based Targets initiative (SBTi) and are designed to support the global effort to limit warming to 1.5°C. Furthermore, Cencora is committed to achieving net zero emissions by 2050 for both Scope 1 and Scope 2 emissions, demonstrating a long-term vision for sustainability. The company's proactive stance on climate action is indicative of its commitment to reducing its environmental impact within the healthcare sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2024 | |
|---|---|---|
| Scope 1 | 98,742,000 | 000,000,000 |
| Scope 2 | 110,191,000 | 00,000,000 |
| Scope 3 | 19,881,916,000 | 00,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cencora, Inc. is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
